PMID: 16633299Apr 25, 2006Paper

Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial

Gastroentérologie Clinique Et Biologique
E MitryP Rougier

Abstract

The efficacy and benefit of second-line chemotherapy in advanced pancreatic adenocarcinoma has never been demonstrated although it is regularly used. A randomized phase II study evaluating oxaliplatin alone (OXA), infusional 5-fluorouracil alone (5-FU) and an oxaliplatin/infusional 5-FU combination (OXFU) in untreated advanced pancreatic adenocarcinoma has been conducted. In this trial, a second-line treatment with the OXFU regimen (OXA 130 mg/m2 2-h intravenous (i.v.) infusion combined with 5-FU (1000 mg/m2/day, continuous i.v., days 1-4), every 3 weeks) was offered to patients progressing after single agent treatment. Eighteen out of 32 patients (12 males, median age 57 years) treated in the single agent arms received the OXFU combination in second-line treatment. WHO performance status was at least 2 in 61% of the patients. There was no objective response and 3 patients (17%) had a disease stabilisation. Median time to progression from the start of second-line treatment was 0.9 months. Median overall survival was 4.9 months from the start of front-line therapy and 1.3 months from the start of second-line therapy. The results of this trial bring arguments to support a modest value of second-line chemotherapy for advanced panc...Continue Reading

References

Jan 1, 1981·Cancer·A B MillerA Winkler
Jun 1, 1994·The British Journal of Surgery·K R PalmerR C Leonard
Nov 1, 1995·Cancer·J E NiederhuberH R Menck
Aug 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B GlimeliusC Svensson
Mar 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C LouvetA de Gramont
Oct 16, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M L RothenbergJ L Abbruzzese

❮ Previous
Next ❯

Citations

Apr 10, 2008·Cancer Chemotherapy and Pharmacology·Chigusa MorizaneEiichiro Suzuki
Sep 4, 2008·Cancer Chemotherapy and Pharmacology·Yoon Jae KimSi Young Song
Mar 1, 2010·Therapeutic Advances in Medical Oncology·Ben Lawrence, Michael Findlay
Mar 8, 2014·World Journal of Gastroenterology : WJG·Evan J Walker, Andrew H Ko
Sep 18, 2009·Cancer Treatment Reviews·Ana CustodioEduardo Díaz-Rubio
Apr 24, 2007·Seminars in Oncology·Michel DucreuxDavid Malka
Oct 21, 2015·Critical Reviews in Oncology/hematology·Adnan M NagrialDesmond Yip
May 15, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·O E RahmaT F Greten
Mar 21, 2018·The Cochrane Database of Systematic Reviews·Venessa ChinDesmond Yip
Feb 6, 2009·American Journal of Clinical Oncology·Anna NovarinoLibero Ciuffreda
Apr 12, 2008·Expert Review of Anticancer Therapy·Andreas Hilbig, Helmut Oettle
Jul 2, 2010·British Journal of Pharmacology·Gabriela B IwanskiH Phillip Koeffler
Sep 18, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Ibrahim Vedat BayogluMustafa Oktay Tarhan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.